These targets were highly enriched in insulin resistance (IR), insulin pathway, adipocytokine pathway, AMPK pathway, T2DM, forkhead box protein O (FoxO) pathway, nonalcoholic fatty liver disease (NAFLD), mammalian target of rapamycin (mTOR) pathway, hypoxia-inducible factor 1 (HIF-1) pathway, glucagon pathway, and so on. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.